Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
72.94
-0.77 (-1.04%)
At close: Nov 13, 2026, 4:00 PM EST
76.77
+3.83 (5.25%)
After-hours: Nov 13, 2026, 7:55 PM EST
Corcept Therapeutics Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Corcept Therapeutics stock has a consensus rating of "Buy" and an average price target of $142.6. The average 1-year stock price forecast is 95.50% higher than the current stock price, while the lowest is $50 (-31.45%) and the highest is $173 (+137.18%).
Price Target: $142.6 (+95.50%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Corcept Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 2 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 1 | 1 | 1 | 1 | 1 |
| Total | 6 | 4 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $161 | Buy | Reiterates | $161 | +120.73% | Nov 5, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $165 | Buy | Maintains | $165 | +126.21% | Nov 5, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $165 → $173 | Buy | Reiterates | $165 → $173 | +137.18% | Nov 4, 2026 |
| Truist Financial | Truist Financial | Buy Initiates $50 → $164 | Buy | Initiates | $50 → $164 | +124.84% | Aug 18, 2026 |
| Wolfe Research | Wolfe Research | Sell Maintains $50 | Sell | Maintains | $50 | -31.45% | Jul 30, 2026 |
Financial Forecast
Revenue This Year
1.16B
from 761.41M
Increased by 52.09%
Revenue Next Year
1.68B
from 1.16B
Increased by 44.73%
EPS This Year
2.13
from 0.82
Increased by 160.16%
EPS Next Year
4.22
from 2.13
Increased by 97.81%
EPS and Forward PE are based on non-GAAP adjusted numbers.